List of Excipients in Branded Drug XARELTO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	XARELTO	rivaroxaban	50090-3625	CELLULOSE, MICROCRYSTALLINE
A-S Medication Solutions	XARELTO	rivaroxaban	50090-3625	CROSCARMELLOSE SODIUM
A-S Medication Solutions	XARELTO	rivaroxaban	50090-3625	FERRIC OXIDE RED

Xarelto Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 2, 2026

Xarelto (rivaroxaban) has a mature oral solid-dose franchise with additional commercial value in pediatric and adult oral-suspension formulations. Its excipient strategy is centered on improving dissolution of a poorly soluble active ingredient, maintaining dose uniformity across strengths, enabling film-coated tablets, and providing a palatable suspension for patients who cannot swallow tablets. The strongest near-term opportunities are generic and authorized-generic development, excipient substitution, pediatric delivery, lactose-free or low-surfactant formulations, and supply-chain diversification.

What excipients are used in Xarelto tablets?

Xarelto tablets use conventional excipients selected for dissolution, mechanical strength, disintegration, coating, identification, and manufacturing consistency. The FDA labeling identifies the principal excipients as follows:

Function	Excipient used in Xarelto tablets
Diluent and compression aid	Microcrystalline cellulose
Diluent	Lactose monohydrate
Disintegrant	Croscarmellose sodium
Binder and film former	Hypromellose
Lubricant	Magnesium stearate
Surfactant and wetting agent	Sodium lauryl sulfate
Colorant	Ferric oxide, strength-dependent

The 2.5-mg, 10-mg, 15-mg, and 20-mg tablets use substantially similar excipient systems, with color variation supporting dose identification. The 15-mg and 20-mg strengths have food-related administration requirements, while the 2.5-mg and 10-mg strengths can be administered with or without food according to the FDA label (FDA, 2024a).

Why does Xarelto use sodium lauryl sulfate?

Sodium lauryl sulfate, or SLS, is likely included to improve wetting and dissolution of rivaroxaban. Rivaroxaban has low aqueous solubility and is classified as a Biopharmaceutics Classification System Class II compound, meaning dissolution can limit absorption.

SLS can improve contact between the hydrophobic drug particles and gastrointestinal fluid. Its inclusion creates several development considerations:

• SLS level must remain within a controlled range because excess surfactant can affect tablet hardness, friability, dissolution, and gastrointestinal tolerability.
• A generic developer replacing SLS must demonstrate equivalent dissolution and bioequivalence.
• SLS-free formulations may offer a commercial differentiation point, but they require a replacement wetting or solubilization strategy.
• The impact of surfactant substitution can vary across dose strengths because the drug-to-excipient ratio changes.

Potential replacement systems include poloxamers, sodium docusate, low levels of polysorbates, copovidone-based solid dispersions, surfactant-containing granules, and engineered drug particles. Each alternative raises separate questions about impurity formation, stability, scale-up, and regulatory comparability.

How does Xarelto’s excipient system support dissolution and bioavailability?

The tablet platform combines particle wetting, rapid disintegration, and adequate mechanical strength.

Rivaroxaban is dispersed within a compressed matrix containing microcrystalline cellulose, lactose, croscarmellose sodium, and SLS. After ingestion, the disintegrant breaks up the tablet, while the surfactant improves wetting. The use of a soluble diluent such as lactose can support rapid penetration of fluid into the tablet matrix. Hypromellose contributes to film coating and may also affect the surface properties of the finished tablet.

The main technical risks are:

1. Inadequate wetting of rivaroxaban particles.
2. Slow tablet disintegration caused by excessive compression or lubricant.
3. Dissolution variability caused by changes in particle size or solid-state properties.
4. Segregation of low-dose blends, particularly the 2.5-mg strength.
5. Food-effect differences at higher doses.

For a generic or follow-on product, dissolution matching is more important than simply copying the qualitative excipient list. The critical formulation variables include rivaroxaban particle size, surface area, polymorphic or amorphous content, granulation method, SLS concentration, compression force, tablet porosity, and coating weight.

What excipients are used in Xarelto oral suspension?

Xarelto has an oral-suspension granule formulation for pediatric and selected adult patients. The granules contain excipients that support suspension stability, preservation, taste, reconstitution, and dose delivery.

The FDA prescribing information identifies the formulation as containing:

• Citric acid anhydrous
• Hypromellose
• Mannitol
• Microcrystalline cellulose
• Sodium benzoate
• Sucralose
• Xanthan gum

The product is supplied as granules that are reconstituted with water to produce a 1-mg/mL suspension. The formulation is administered using a calibrated oral syringe, which is important because pediatric dosing is weight-based (FDA, 2024a).

What is the commercial value of the oral suspension?

The suspension expands the addressable population beyond adults who can swallow tablets. It supports use in pediatric venous thromboembolism and thromboprophylaxis settings, including children with congenital heart disease, cancer-associated thrombosis, or other thrombotic conditions.

The main commercial barriers are higher manufacturing and distribution costs than tablets, shorter in-use stability after reconstitution, packaging complexity, and the need for an oral syringe. These barriers also create differentiation opportunities:

• Improved taste masking for children.
• Lower sedimentation and easier redispersion.
• Simplified reconstitution.
• Longer in-use stability.
• Unit-dose or ready-to-use presentations.
• Formulations compatible with feeding tubes.
• Reduced preservative load.
• Improved dose accuracy at very low volumes.

A generic suspension must establish pharmaceutical equivalence and bioequivalence while controlling particle size, sedimentation, viscosity, redispersibility, preservative effectiveness, microbial limits, and dose uniformity. These requirements make the suspension a more technically demanding target than the immediate-release tablet.

What formulation opportunities exist for generic rivaroxaban?

The highest-value formulation opportunities are concentrated in platform improvements rather than new therapeutic indications.

SLS-reduced or SLS-free tablets

An SLS-reduced formulation could target patients with excipient sensitivity or manufacturers seeking a differentiated label. A successful design would need to preserve dissolution across physiologic pH conditions and support bioequivalence at the 15-mg and 20-mg strengths, where food affects exposure.

Possible approaches include:

• Micronized or nanomilled rivaroxaban.
• Spray-dried dispersions.
• Wetting agents with lower gastrointestinal concern.
• Porous granules.
• Co-processed microcrystalline cellulose systems.
• Amorphous solid dispersions.

Lactose-free tablets

Xarelto tablets contain lactose monohydrate. A lactose-free version could address patients with lactose intolerance, although the clinical relevance of the small quantity in a tablet would vary by patient. Substitutes include mannitol, anhydrous dibasic calcium phosphate, silicified microcrystalline cellulose, starch derivatives, and direct-compression polyols.

The main development issue is preserving tablet tensile strength and dissolution while avoiding an increase in tablet size.

Pediatric multiparticulates

Multiparticulate granules or mini-tablets could offer an alternative to a conventional suspension. These systems may improve stability and reduce liquid-handling costs, but they must address dose flexibility, swallowability, taste masking, and administration through feeding tubes.

Long-acting or modified-release products

A modified-release rivaroxaban product would have greater regulatory and technical risk. Rivaroxaban is already used at different doses and dosing frequencies depending on indication. A sustained-release version could reduce dosing frequency, but it would require a new pharmacokinetic profile and potentially a 505(b)(2) pathway in the United States. The commercial case would depend on adherence benefits and differentiation from low-cost generics.

What patents protect Xarelto and its formulations?

The principal active-ingredient patent is U.S. Patent No. 7,157,456, which covers rivaroxaban-related compounds and is assigned to Bayer intellectual-property entities. The patent has been central to U.S. generic-entry litigation and settlement activity.

Xarelto’s protection is not limited to one patent category. Relevant patent and regulatory layers include:

Protection layer	Commercial relevance
Compound patent	Protects rivaroxaban as the active pharmaceutical ingredient
Formulation patents	May address solid dosage forms, granules, suspensions, or excipient combinations
Method-of-use patents	May cover prevention or treatment of specific thrombotic conditions
Pediatric exclusivity	Can delay certain FDA approvals or add regulatory protection
Orange Book listings	Identify patents submitted for approved products
Settlement agreements	Can establish negotiated generic-entry dates

The Orange Book should be evaluated by product strength and dosage form because tablet and suspension listings may not have identical patent coverage. A formulation patent that covers a suspension does not necessarily block an ANDA for tablets, while a compound patent can affect all dosage forms containing rivaroxaban (FDA, 2024b).

When does Xarelto lose exclusivity?

Xarelto’s core U.S. small-molecule patent protection is reaching the end of its commercial life, with generic-entry timing shaped by patent litigation and settlement agreements rather than by the compound patent alone. Regulatory exclusivity and patent expiration are separate concepts. A product can lose FDA exclusivity while remaining subject to enforceable patents, or remain commercially protected through litigation settlements after regulatory exclusivity has ended.

Publicly reported settlements involving Janssen and generic manufacturers have established staggered or negotiated launch dates for certain rivaroxaban products. The dates and scope depend on the manufacturer, dosage form, and patent claims at issue. Generic entrants must also assess pediatric suspension patents and any later-issued formulation patents separately.

What is the Orange Book status of Xarelto?

The FDA Orange Book identifies Xarelto as an approved rivaroxaban product with multiple strengths and dosage forms. Orange Book review is relevant to:

• Patent certification requirements for an ANDA.
• Paragraph IV challenges.
• Whether a listed patent covers the active ingredient, formulation, or method of use.
• Regulatory exclusivity periods.
• Potential 30-month stays following patent litigation.

An ANDA applicant may file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or will not be infringed. If the patent holder sues within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments (FDA, 2024c).

Which companies are challenging Xarelto patents?

Multiple generic manufacturers have pursued U.S. rivaroxaban opportunities, including companies associated with Paragraph IV litigation and settlements involving Janssen. Publicly reported participants have included manufacturers such as Teva, Mylan, Sun Pharma, Hetero, and other ANDA applicants, depending on the product and settlement period.

The competitive field should be divided into:

1. Tablet ANDA applicants.
2. Applicants targeting multiple strengths.
3. Applicants targeting the oral suspension.
4. Authorized-generic or licensed suppliers.
5. Manufacturers with non-U.S. approvals that may later seek U.S. entry.

The largest commercial risk to the branded product comes from simultaneous tablet launches across several strengths. Suspension entry is likely to be slower because of formulation, manufacturing, device, and pediatric bioequivalence requirements.

What patent litigation affects Xarelto?

Xarelto litigation has focused on compound patents, formulation claims, method-of-use claims, and the timing of generic entry. The litigation record includes district-court actions triggered by Paragraph IV certifications, settlement agreements, and subsequent disputes over the scope of negotiated entry rights.

For commercial planning, litigation should be analyzed at the claim level:

• Compound claims create the broadest potential barrier.
• Formulation claims may affect only particular dosage forms.
• Method-of-use claims may be relevant to labeling and skinny-label strategy.
• Settlement terms may permit entry for some strengths or indications before others.
• Authorized-generic arrangements can alter price erosion even before an independent generic launch.

Are biosimilar risks relevant to Xarelto?

No. Rivaroxaban is a synthetic small molecule, not a biologic. Xarelto faces generic-drug risk under the ANDA pathway, not biosimilar competition under the Biologics Price Competition and Innovation Act. The relevant competitive mechanisms are Paragraph IV litigation, ANDA approval, authorized generics, patent settlements, and post-entry pricing.

How strong is the Xarelto patent estate?

Xarelto’s historical patent estate has been commercially strong because the compound patent covered the active ingredient across indications and dosage forms. Its remaining strength is lower as the core patent term ends and generic manufacturers reach settlement-based entry dates.

The estate is strongest where:

• A valid compound claim remains enforceable.
• A formulation patent covers the exact dosage form.
• A method-of-use claim is difficult to omit from the generic label.
• A settlement restricts launch timing.
• Manufacturing know-how creates a practical, rather than purely legal, barrier.

The estate is weaker where:

• Alternative excipient systems avoid formulation claims.
• A generic can enter with a non-infringing manufacturing process.
• Method-of-use claims can be carved out.
• Multiple manufacturers have secured entry rights.
• The product can be made using widely available excipients and conventional equipment.

What licensing deals support Xarelto commercialization?

Xarelto is commercialized through a collaboration between Bayer and Johnson & Johnson’s Janssen Pharmaceuticals. Bayer has historically led commercialization in many markets outside the United States, while Janssen has been responsible for U.S. commercialization. The collaboration affects patent ownership, regulatory filings, litigation strategy, and revenue allocation.

For generic and formulation companies, the relevant commercial opportunity is usually a license or supply arrangement rather than a novel discovery license. Potential structures include:

• Authorized-generic supply agreements.
• Regional commercialization licenses.
• Pediatric formulation licenses.
• Contract manufacturing arrangements.
• Co-development of suspension or multiparticulate products.
• Excipient or delivery-platform licenses.

What revenue exposure does generic Xarelto entry create?

Xarelto is one of Bayer’s largest pharmaceutical products. Bayer reported 2023 Xarelto sales of approximately €4.5 billion, making generic entry a material revenue event for the company (Bayer, 2024).

Revenue erosion will depend on:

• The timing of the first U.S. generic launch.
• The number of simultaneous entrants.
• Whether an authorized generic launches.
• Price discounts and rebate behavior.
• Continued use in high-volume stroke-prevention indications.
• Uptake of pediatric suspension products.
• Generic penetration outside the United States.
• Patent outcomes in major markets.

Tablet markets generally experience rapid price erosion after multiple generic entrants. Pediatric suspension markets are smaller and may retain higher margins because of manufacturing complexity, limited competitors, and specialized packaging.

How does Xarelto compare with Eliquis from an excipient and patent perspective?

Xarelto and Eliquis both compete in oral anticoagulation, but their lifecycle profiles differ.

Factor	Xarelto	Eliquis
Active ingredient	Rivaroxaban	Apixaban
Drug type	Small molecule	Small molecule
Primary dosage forms	Tablets and oral suspension	Tablets
Pediatric formulation	Available as oral suspension	More limited commercial pediatric formulation profile
Key formulation issue	Low solubility and dissolution control	Dose uniformity, dissolution, and tablet platform
Biosimilar exposure	None	None
Generic pathway	ANDA	ANDA
Commercial differentiation	Once-daily dosing for several indications and pediatric suspension	Strong atrial-fibrillation and venous-thromboembolism franchise

Xarelto has a potentially stronger formulation opportunity because its oral suspension provides a differentiated dosage form. Eliquis has substantial commercial scale, but a competing generic developer may find Xarelto suspension manufacturing more difficult than standard tablet entry.

What generic launch scenarios exist for Xarelto?

Three scenarios are commercially relevant.

Early multi-player tablet entry

Several manufacturers launch close together after settlement or patent clearance. This produces rapid price erosion, distributor inventory competition, and lower expected returns for later entrants.

Limited first-wave entry

One or two manufacturers enter first under settlement terms. Early entrants may capture attractive margins, particularly if they have authorized-generic status or preferred channel access.

Delayed suspension entry

Tablet generics reach the market before oral-suspension competitors. Pediatric and dysphagia patients remain concentrated in the branded product until a technically equivalent suspension becomes available.

What geographic coverage does Xarelto have?

Xarelto is marketed broadly across the United States, Europe, Japan, China, and other major pharmaceutical markets. Patent and exclusivity analysis must be conducted jurisdiction by jurisdiction because:

• Patent terms differ.
• Supplementary protection certificates may extend European protection.
• Pediatric extensions vary.
• Regulatory data exclusivity is not uniform.
• Settlement agreements may apply only to the United States.
• Approved strengths and dosage forms differ by country.

A formulation patent with limited U.S. coverage may have greater practical value in Europe or emerging markets if local generic competition is less developed. Conversely, high-volume markets such as the United States and major European countries are likely to attract the greatest number of ANDA or equivalent applicants.

What manufacturing and IP barriers affect rivaroxaban products?

Rivaroxaban itself is available from multiple active pharmaceutical ingredient suppliers, but commercial-scale manufacturing still requires control of particle attributes, impurities, residual solvents, polymorphic form, and batch-to-batch dissolution performance.

The main manufacturing barriers are:

• Low-dose content uniformity.
• Consistent drug particle size.
• SLS or alternative surfactant distribution.
• Tablet compression and coating control.
• Suspension sedimentation and redispersibility.
• Preservative effectiveness.
• Accurate pediatric dosing.
• Stability after reconstitution.
• Packaging compatibility with the suspension.

Excipient procurement is not usually the principal legal barrier. The greater risk is whether a particular excipient combination, process sequence, or dosage form falls within a formulation patent claim. A company can reduce freedom-to-operate risk through a deliberately engineered formulation that uses different excipient ratios, a distinct granulation process, or a separate suspension architecture.

Key Takeaways

• Xarelto uses a conventional tablet excipient system built around microcrystalline cellulose, lactose, croscarmellose sodium, hypromellose, magnesium stearate, SLS, and colorants.
• SLS is commercially important because rivaroxaban has low aqueous solubility and dissolution can limit exposure.
• The oral suspension uses hypromellose, xanthan gum, mannitol, sodium benzoate, sucralose, citric acid, and microcrystalline cellulose.
• SLS-free, lactose-free, pediatric multiparticulate, and improved suspension products are the clearest formulation opportunities.
• Xarelto faces generic competition, not biosimilar competition.
• Compound-patent expiry, Orange Book listings, Paragraph IV litigation, and settlement agreements determine practical U.S. entry timing.
• Tablet generic entry is likely to produce faster price erosion than suspension entry.
• Bayer’s approximately €4.5 billion in 2023 Xarelto sales creates significant exposure to generic substitution.
• Excipient freedom to operate depends on formulation claims, process claims, and dosage-form-specific patents.
• The pediatric suspension is the most defensible commercial niche because of its specialized formulation and packaging requirements.

FAQs

Can a generic company copy Xarelto’s excipients exactly?

Yes, subject to regulatory requirements and patent freedom-to-operate. Exact excipient matching does not by itself establish bioequivalence, and the applicant must control particle size, manufacturing process, dissolution, and stability.

Is sodium lauryl sulfate essential to rivaroxaban absorption?

SLS is not necessarily chemically essential, but it can be functionally important for wetting and dissolution. A replacement formulation must demonstrate equivalent product performance and bioavailability.

Can a company commercialize a lactose-free Xarelto generic?

Potentially. A lactose-free formulation would require formulation development, stability testing, dissolution matching, and ANDA approval. The substitute excipient system must preserve tablet quality and bioequivalence.

Is Xarelto oral suspension protected separately from Xarelto tablets?

Potentially. Tablet and suspension formulations can have different Orange Book listings, formulation claims, regulatory requirements, and settlement terms. Each dosage form requires separate patent and regulatory analysis.

What is the most attractive excipient opportunity around rivaroxaban?

A robust pediatric suspension or SLS-reduced, lactose-free tablet platform offers the clearest differentiation. The suspension has higher technical barriers, while the tablet opportunity has greater market volume but more intense generic competition.

References

1. Bayer AG. (2024). Annual report 2023. Bayer AG.

2. U.S. Food and Drug Administration. (2024a). Xarelto (rivaroxaban) prescribing information. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024c). Guidance for industry: 180-day exclusivity and abbreviated new drug applications. U.S. Department of Health and Human Services.

5. U.S. Patent No. 7,157,456. (2007). Oxazolidinone derivatives and their use as medicaments. U.S. Patent and Trademark Office.